2016
Association of Guideline-Based Admission Treatments and Life Expectancy After Myocardial Infarction in Elderly Medicare Beneficiaries
Bucholz EM, Butala NM, Normand SL, Wang Y, Krumholz HM. Association of Guideline-Based Admission Treatments and Life Expectancy After Myocardial Infarction in Elderly Medicare Beneficiaries. Journal Of The American College Of Cardiology 2016, 67: 2378-2391. PMID: 27199062, PMCID: PMC5097252, DOI: 10.1016/j.jacc.2016.03.507.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAspirinFemaleFollow-Up StudiesGuideline AdherenceHospitalizationHumansLife ExpectancyMaleMedicareMyocardial InfarctionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPractice Guidelines as TopicThrombolytic TherapyTime-to-TreatmentUnited StatesConceptsAcute myocardial infarctionPrimary percutaneous coronary interventionGuideline-based therapyYears of lifeAdmission therapyLife expectancyMyocardial infarctionMedicare beneficiariesCox proportional hazards regressionAcute reperfusion therapyLate survival benefitReceipt of aspirinPercutaneous coronary interventionLong-term outcomesProportional hazards regressionCooperative Cardiovascular ProjectElderly Medicare beneficiariesDose-response relationshipAssociation of GuidelineShort life expectancyLonger life expectancyReperfusion therapyCoronary interventionD2B timeElderly patients
2001
Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure
Chen Y, Wang Y, Radford M, Krumholz H. Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. American Heart Journal 2001, 141: 410-417. PMID: 11231438, DOI: 10.1067/mhj.2001.113227.Peer-Reviewed Original ResearchConceptsACE inhibitorsHeart failureClinical trialsSystolic dysfunctionElderly patientsLow dosesConfirmed heart failureDosage of angiotensinRepresentative elderly cohortDose-response relationshipHospital dischargeClinical factorsGuideline recommendationsElderly cohortMedication dataMedical recordsAdministrative databasesConnecticut hospitalsPractice guidelinesEnzyme inhibitorsPatientsLower mortalityHigh dosesDosesMortality